---

Serum albumin level as a marker to predict morbidity in post COVID-19 patients admitted in a rural critical care unit

Full Text PDF

---

Original Article

Author Details : Jay Manojkumar Bhensdadia, M.K. Chaitanya Krishna, Akshaya N. Shetti*, Bhavika Singla, Rachita G Mustilwar

Volume : 9, Issue : 3, Year : 2022

Article Page : 138-140

https://doi.org/10.18231/j.ijpca.2022.026

Suggest article by email

Get Permission

Abstract

Background: Covid-19 raged for more than two years in almost all parts of the world including India and the long term effects are yet to be studied. Presently with the availability of vaccine has reduced the suffering even after covid-19 infection. This study is aimed to understand the patient with past history of covid-19 infection and serum albumin levels and the outcome.
Materials and Methods: A total of 52 patients admitted to intensive care unit with past history of COVID-19 infection, between 01.11.2021 and 31.01.2022, were enrolled in this study. The required data were collected from the records.
Results: Of the total 52 patients included in the study, 41 (78.85%) were males and 11 (21.15%) were females. Amongst these 52 patients, 18 (34.6%) were detected with hypoalbuminemia. Higher association of co-morbidities (22.22% patients) was seen in patients with hypoalbuminemia. Death rate in hypoalbuminemia group was 11.11% while that in those with normal albumin levels was only 2.94%.
Conclusion: Patients with hypoalbuminemia and previous covid 19 infection were having higher mortality rate as compared to normoalbuminemia.

Keywords: Hypoalbuminemia, Serum

How to cite : Bhensdadia J M, Krishna M C, Shetti A N, Singla B, Mustilwar R G, Serum albumin level as a marker to predict morbidity in post COVID-19 patients admitted in a rural critical care unit. Int J Pharm Chem Anal 2022;9(3):138-140

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.